Aug 14, 2025
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
May 14, 2025
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 05, 2025
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Mar 24, 2025
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
Mar 10, 2025
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
Feb 04, 2025
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Dec 23, 2024
Protalix BioTherapeutics Issues 2025 Letter to Stockholders
Dec 09, 2024
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa
Nov 07, 2024
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
Oct 25, 2024
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Sep 04, 2024
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Sep 03, 2024
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes
May 10, 2024
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results
May 03, 2024
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024
Mar 14, 2024
Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results
Feb 23, 2024
Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference
Feb 23, 2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
Feb 18, 2021
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
Feb 11, 2021
Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common Stock
Feb 11, 2021
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery